作为用于治疗多种疾病的二酰甘油酰基转移酶2（DGAT2）抑制剂的吡唑并吡啶和三唑并吡啶衍生物
Pyrazolopyridine and Triazolopyridine Derivatives as DGAT2 Inhibitors for Treating Multiple Diseases.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2024 Oct 14;15(11):1806-1807. doi: 10.1021/acsmedchemlett.4c00485. eCollection 2024 Nov 14.
Abstract
Provided herein are novel pyrazolopyridine and triazolopyridine derivatives as DGAT2 inhibitors, pharmaceutical compositions, use of such compounds in treating multiple diseases, and processes for preparing such compounds.
摘要
本文提供了作为二酰甘油酰基转移酶2（DGAT2）抑制剂的新型吡唑并吡啶和三唑并吡啶衍生物、药物组合物、此类化合物在治疗多种疾病中的用途以及制备此类化合物的方法。
相似文献
1
Pyrazolopyridine and Triazolopyridine Derivatives as DGAT2 Inhibitors for Treating Multiple Diseases.作为用于治疗多种疾病的二酰甘油酰基转移酶2（DGAT2）抑制剂的吡唑并吡啶和三唑并吡啶衍生物
ACS Med Chem Lett. 2024 Oct 14;15(11):1806-1807. doi: 10.1021/acsmedchemlett.4c00485. eCollection 2024 Nov 14.
2
Novel Triazolopyridine Derivatives as DGAT2 Inhibitors for Treating Multiple Diseases.作为用于治疗多种疾病的二酰甘油酰基转移酶2（DGAT2）抑制剂的新型三唑并吡啶衍生物
ACS Med Chem Lett. 2024 Aug 21;15(9):1435-1436. doi: 10.1021/acsmedchemlett.4c00408. eCollection 2024 Sep 12.
3
Treatment of Metabolic Disorders Using Novel DGAT2 Inhibitors: Pyrazolopyridine and Triazolopyridine Derivatives.使用新型二酰甘油酰基转移酶2（DGAT2）抑制剂治疗代谢紊乱：吡唑并吡啶和三唑并吡啶衍生物
ACS Med Chem Lett. 2024 Jul 25;15(8):1199-1200. doi: 10.1021/acsmedchemlett.4c00329. eCollection 2024 Aug 8.
4
Novel Imidazopyridine and Imidazopyridazine Derivatives as DGAT2 Inhibitors for Treating Multiple Diseases.新型咪唑并吡啶和咪唑并哒嗪衍生物作为治疗多种疾病的二酰甘油酰基转移酶2（DGAT2）抑制剂
ACS Med Chem Lett. 2024 Jul 3;15(8):1180-1181. doi: 10.1021/acsmedchemlett.4c00286. eCollection 2024 Aug 8.
5
Novel Phenylpiperidine Derivatives as QPCT and QPCTL Inhibitors for Treating Cancer or Fibrotic Diseases.新型苯基哌啶衍生物作为QPCT和QPCTL抑制剂用于治疗癌症或纤维化疾病。
ACS Med Chem Lett. 2024 Oct 30;15(11):1826-1827. doi: 10.1021/acsmedchemlett.4c00495. eCollection 2024 Nov 14.
6
Novel 3-Pyrrolidineindole Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis and Mental Illnesses Such as Depression and Post-Traumatic Stress Disorder.新型3-吡咯烷吲哚衍生物作为5-羟色胺能致幻剂用于治疗精神病以及抑郁症和创伤后应激障碍等精神疾病。
ACS Med Chem Lett. 2024 Dec 10;16(1):18-19. doi: 10.1021/acsmedchemlett.4c00581. eCollection 2025 Jan 9.
7
Novel Triazine Derivatives as NLRP3 Inhibitors for Treating Asthma or COPD.新型三嗪衍生物作为治疗哮喘或慢性阻塞性肺疾病的NLRP3抑制剂
ACS Med Chem Lett. 2025 Jan 24;16(2):200-201. doi: 10.1021/acsmedchemlett.5c00020. eCollection 2025 Feb 13.
8
Novel Heterocyclic Compounds as Monoacylglycerol Lipase Inhibitors for Treating Multiple Diseases.作为用于治疗多种疾病的单酰甘油脂肪酶抑制剂的新型杂环化合物。
ACS Med Chem Lett. 2024 Jun 21;15(7):994-995. doi: 10.1021/acsmedchemlett.4c00261. eCollection 2024 Jul 11.
9
Novel Triazines as NLRP3 Inhibitors for Treating Multiple Diseases.新型三嗪类化合物作为治疗多种疾病的NLRP3抑制剂
ACS Med Chem Lett. 2024 Nov 18;15(12):2099-2100. doi: 10.1021/acsmedchemlett.4c00552. eCollection 2024 Dec 12.
10
Novel Imidazotriazine Derivatives as IL-17 Modulators for Treating Inflammatory and Autoimmune Disorders.新型咪唑并三嗪衍生物作为治疗炎症和自身免疫性疾病的白细胞介素-17调节剂
ACS Med Chem Lett. 2024 Dec 10;16(1):12-13. doi: 10.1021/acsmedchemlett.4c00573. eCollection 2025 Jan 9.
本文引用的文献
1
Novel Triazolopyridine Derivatives as DGAT2 Inhibitors for Treating Multiple Diseases.作为用于治疗多种疾病的二酰甘油酰基转移酶2（DGAT2）抑制剂的新型三唑并吡啶衍生物
ACS Med Chem Lett. 2024 Aug 21;15(9):1435-1436. doi: 10.1021/acsmedchemlett.4c00408. eCollection 2024 Sep 12.
2
Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?肥胖与 MASLD：减轻体重是否是治疗代谢性肝病的关键？
Metabolism. 2024 Aug;157:155937. doi: 10.1016/j.metabol.2024.155937. Epub 2024 May 21.
3
Perilipins: A family of five fat-droplet storing proteins that play a significant role in fat homeostasis.脂滴包被蛋白家族：一类具有重要功能的脂肪滴储存蛋白，在脂肪动态平衡中发挥重要作用。
J Cell Biochem. 2024 Jun;125(6):e30579. doi: 10.1002/jcb.30579. Epub 2024 May 15.
4
The lipid droplet lipidome.脂滴脂质组学。
FEBS Lett. 2024 May;598(10):1215-1225. doi: 10.1002/1873-3468.14874. Epub 2024 Apr 11.
5
The role of DGAT1 and DGAT2 in regulating tumor cell growth and their potential clinical implications.DGAT1 和 DGAT2 在调节肿瘤细胞生长中的作用及其潜在的临床意义。
J Transl Med. 2024 Mar 18;22(1):290. doi: 10.1186/s12967-024-05084-z.
6
Pharmacologic inhibition of lipogenesis for the treatment of NAFLD.通过药物抑制脂肪生成来治疗非酒精性脂肪性肝病。
J Hepatol. 2024 Feb;80(2):362-377. doi: 10.1016/j.jhep.2023.10.042. Epub 2023 Nov 15.
Zotero 插件